CPC A61K 31/7076 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61P 31/14 (2018.01)] | 37 Claims |
1. A method for the treatment of COVID-19 caused by the SARS-CoV-2 virus in a human host in need thereof comprising administering an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, wherein:
R1 is methyl;
R2 is aryl, or aryl(C1-C4alkyl);
R3 is hydrogen or C1-6alkyl;
R4a and R4b are independently selected from hydrogen, C1-6alkyl, and C3-7cycloalkyl; and
R5 is C1-6alkyl, C1-6haloalkyl, C3-7cycloalkyl, aryl(C1-C4alkyl)-, aryl, heteroaryl, or heteroalkyl.
|